分红方面，欧林生物A股上市后累计派现1543.40万元。 机构持仓方面，截止2025年9月30日，欧林生物十大流通股东中，兴全合润混合A（163406）位居第五 大流通股东，持股1544.02万股，持股数量较上期不变。兴全合宜混合A（163417）位居第七大流通股 东，持股892.14万股，持股数量较上期不变。兴全商业模式混合(LOF)A（163415）位居第十大流通股 东，持股464.12万股，为新进股东。 责任编辑：小浪快报 资料显示，成都欧林生物科技股份有限公司位于四川省成都高新区天欣路99号，成立日期2009年12月11 日，上市日期2021年6月8日，公司主营业务涉及人用疫苗的研发、生产及销售。主营业务收入构成为： 吸附破伤风疫苗90.99%，A群C群脑膜炎球菌多糖结合疫苗4.49%，b型流感嗜血杆菌结合疫苗3.99%， 其他(补充)0.47%，精制破伤风类毒素原液0.07%。 截至9月30日，欧林生物股东户数1.02万，较上期增加56.42%；人均流通股39746股，较上期减少 36.07%。2025年1月-9月，欧林生物实现营业收入5.07亿元，同比增长31.11%；归母净利润4747.98万 ...

投资者可于 2025 年 11 月 24 日(星期一)至 11 月 28 日(星期五)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@olymvax.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 证券代码：688319 证券简称：欧林生物 公告编号：2025-064 成都欧林生物科技股份有限公司关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 成都欧林生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年前三季度的经营成果、财务状况，公司计划于 2025 年 12 月 01 日(星期 一)上午 10:00-11:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进 行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年前三季度的经 营成果及财务指标的具体情况 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.94% on November 17, with Kexing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Bohui Innovation: Closed at 8.00, up 2.56% with a trading volume of 824,300 shares [1] - ST Weiming: Closed at 8.31, up 2.21% with a trading volume of 60,800 shares [1] - Major decliners included: - Kexing Pharmaceutical: Closed at 34.59, down 7.88% with a trading volume of 53,300 shares [2] - Jinwei: Closed at 26.05, down 7.06% with a trading volume of 123,100 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 1.211 billion yuan from institutional investors, while retail investors contributed a net inflow of 893 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Wanzhe Co.: Net outflow of 37.20 million yuan from institutional investors [3] - Olin Bio: Net inflow of 13.81 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different companies within the sector [3]

Core Insights - On November 14, Oulin Bio's stock rose by 4.29%, with a trading volume of 271 million yuan [1] - The company reported a net financing outflow of 913,200 yuan on the same day, with a total financing and securities balance of 331 million yuan [1] - Oulin Bio's main business involves the research, production, and sales of human vaccines, with significant revenue contributions from various vaccine products [1] Financing and Trading Data - On November 14, Oulin Bio had a financing buy-in of 31.69 million yuan, while the financing balance reached 331 million yuan, accounting for 3.29% of the circulating market value [1] - The financing balance is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - No shares were sold or repaid in the securities lending market on the same day, with a balance of 0 yuan [1] Financial Performance - As of September 30, Oulin Bio reported a total revenue of 507 million yuan for the first nine months of 2025, representing a year-on-year growth of 31.11% [2] - The net profit attributable to shareholders reached 47.48 million yuan, showing a significant increase of 1079.36% compared to the previous period [2] Shareholder and Dividend Information - Since its A-share listing, Oulin Bio has distributed a total of 15.43 million yuan in dividends [3] - As of September 30, 2025, the number of shareholders increased to 10,200, a rise of 56.42%, while the average circulating shares per person decreased by 36.07% to 39,746 shares [2][3] - Notable institutional holdings include XQH Run Mixed A and XQH Yi Mixed A, with stable shareholding numbers [3]

证券代码：688319 证券简称：欧林生物 公告编号：2025-063 一、通知债权人的原由 成都欧林生物科技股份有限公司（以下简称"公司"或"欧林生物"）于 2025 年 10 月 28 日召开第七届董事会第五次会议，并于 2025 年 11 月 14 日召开 2025 年第二次临时股东会，审议通过了《关于回购注销 2023 年限制性股票激励计划首 次授予部分已获授尚未解除限售的第一类限制性股票的议案》，具体内容详见公 司于 2025 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）披露的《成都 欧林生物科技股份有限公司关于回购注销2023年限制性股票激励计划首次授予部 分已获授尚未解除限售的第一类限制性股票的公告》（公告编号：2025-055）。 根据《上市公司股权激励管理办法》等法律法规及公司《2023 年限制性股票 激励计划（草案）》（以下简称"《激励计划（草案）》"、"本激励计划"）、 《2023 年限制性股票激励计划实施考核管理办法》（以下简称"《考核管理办法》"） 的相关规定，鉴于本激励计划首次授予第二个解除限售期公司层面业绩未达到《激 励计划（草案）》和《考核管理办法 ...

北京德恒（成都）律师事务所 关于成都欧林生物科技股份有限公司 2025 年第二次临时股东会的 法律意见 四川省成都市高新区天府大道中段 666 号希顿国际广场 B 座 20 层 电话：028-83338385 传真：028-83338385 邮编：610041 北京德恒（成都）律师事务所 关于成都欧林生物科技股份有限公司 2025年第二次临时股东会的法律意见 北京德恒（成都）律师事务所 关于成都欧林生物科技股份有限公司 2025 年第二次临时股东会的法律意见 京德成律法意字（2025）第 110240 号 致：成都欧林生物科技股份有限公司 成都欧林生物科技股份有限公司（以下简称"公司"）2025 年第二次临时 股东会（以下简称"本次会议"）于 2025 年 11 月 14 日召开。北京德恒（成都） 律师事务所（以下简称"德恒"）受公司委托，指派律师（以下简称"德恒律师"） 出席了本次会议，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东会规则（2025 年修订）》（以下简称"《股东会规则》"）、 《成都欧林生 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-062 成都欧林生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 80 | | --- | --- | | 普通股股东人数 | 80 | | 2、出席会议的股东所持有的表决权数量 | 162,204,483 | | 普通股股东所持有表决权数量 | 162,204,483 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 39.9583 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 39.9583 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长樊绍文先生主持，会议采用现场投票 （ ...

Market Overview - The biopharmaceutical sector increased by 0.3% on November 14, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3990.49, down by 0.97%, while the Shenzhen Component Index closed at 13216.03, down by 1.93% [1] Stock Performance - Jindike (688670) closed at 28.03, up by 19.99% with a trading volume of 105,500 shares and a transaction value of 270 million [1] - Hualan Ting (301207) closed at 25.38, up by 7.22% with a trading volume of 336,800 shares [1] - Other notable performers include: - Saikai Pharmaceutical (300485) at 13.35, up by 4.54% [1] - Olin Bio (616889) at 24.81, up by 4.29% [1] - Wowo Bio (300357) at 33.65, up by 3.03% [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 59.84 million from institutional investors, while retail investors saw a net inflow of 23.85 million [2][3] - Key stocks with significant capital flow include: - Ganli Pharmaceutical (603087) with a net inflow of 62.98 million from institutional investors [3] - Jindike (688670) with a net inflow of 40.32 million from institutional investors [3] - Hualan Ting (301207) with a net inflow of 27.99 million from institutional investors [3]

Core Viewpoint - Oulin Bio experienced a 5.59% increase in stock price, reaching 25.12 CNY per share, with a trading volume of 113 million CNY and a market capitalization of 10.197 billion CNY as of November 14 [1] Company Overview - Chengdu Oulin Biotechnology Co., Ltd. was established on December 11, 2009, and went public on June 8, 2021. The company specializes in the research, production, and sales of human vaccines [1] - The main revenue composition includes: - 90.99% from adsorbed tetanus vaccine - 4.49% from group A and C meningococcal polysaccharide conjugate vaccine - 3.99% from type b Haemophilus influenzae conjugate vaccine - 0.47% from other supplementary products - 0.07% from refined tetanus toxin raw liquid [1] Fund Holdings - Huafu Fund has a significant holding in Oulin Bio, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 600,000 shares, accounting for 7.56% of the fund's net value, making it the fourth-largest holding [2] - The fund has achieved a year-to-date return of 43.03%, ranking 1679 out of 8140 in its category, and a one-year return of 22.35%, ranking 3346 out of 8056 [2] - The fund manager, Liao Qingyang, has been in position for 4 years and 6 days, with a total fund asset size of 216 million CNY and a best return of 22.13% during his tenure [2]

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.08% on November 11, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Stock Performance - Notable gainers included: - Jin Ke (688670) with a closing price of 24.97, up 19.99% on a trading volume of 134,300 shares and a transaction value of 310 million [1] - Kanghua Bio (300841) closed at 83.21, up 6.04% with a trading volume of 57,100 shares [1] - Watson Bio (300142) closed at 12.82, up 2.64% with a trading volume of 942,000 shares [1] - Significant losers included: - Bu Yuan Bio (688765) closed at 86.00, down 8.02% with a trading volume of 107,600 shares [2] - Ao Pu Mai (688293) closed at 59.18, down 3.65% with a trading volume of 17,900 shares [2] - Rongchang Bio (688331) closed at 86.00, down 2.55% with a trading volume of 45,900 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 671 million from institutional investors, while retail investors contributed a net inflow of 335 million [2] - The capital flow for key stocks showed: - Jin Ke had a net inflow of 48.11 million from institutional investors, but a net outflow of 24.49 million from speculative funds [3] - Zhifei Bio (300122) experienced a net inflow of 15.25 million from institutional investors, with a net outflow of 23.20 million from retail investors [3] - Kanghua Bio had a net inflow of 14.35 million from institutional investors, but a net outflow of 23.26 million from speculative funds [3]